Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixekizumab - Eli Lilly

Drug Profile

Ixekizumab - Eli Lilly

Alternative Names: LY-2439821; Taltz

Latest Information Update: 16 Aug 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Oregon Health & Science University; Torii Pharmaceutical
  • Class Antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythrodermic psoriasis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Preregistration Ankylosing spondylitis
  • Phase III Spondylarthritis
  • Phase II Bullous pemphigoid; Pityriasis rubra pilaris; Pyoderma gangrenosum; Rheumatoid arthritis

Most Recent Events

  • 07 Jul 2019 Eli Lily completes a phase I trial in Healthy volunteers in USA (NCT03848403)
  • 26 Jun 2019 Eli Lilly completes the phase III SPIRIT-P2 trial in Psoriatic arthritis (Treatment-experienced) in USA, Australia, Czech Republic, France, Germany, Italy, Poland, Spain, Taiwan and United Kingdom (SC) (NCT02349295)
  • 17 Jun 2019 Efficacy data from a phase III trial in Psoriatic arthritis presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top